Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
George D. Demetri(Dana-Farber Cancer Institute), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Daniel A. Rushing(Dana-Farber/Harvard Cancer Center), Peter Reichardt(Helios Hospital Berlin-Buch), Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Lee D. Cranmer(University of Washington), Thierry Alcindor(McGill University), Ruey-min Lee(Merck Biopharma Co., Ltd. (Japan)), Isabelle Ray‐Coquard(Centre Léon Bérard), Sant P. Chawla(Sarcoma Oncology Center), Richard F. Riedel(Heidelberg University), Emmanuelle Bompas, Frank G. Haluska(Ariadne Diagnostics (United States)), John W. Loewy(Dana-Farber/Harvard Cancer Center), Mohammed Milhem(University of Iowa), P. Dodion(Dana-Farber/Harvard Cancer Center), Arthur P. Staddon(University of Pennsylvania), Axel Le Cesne(Institut Gustave Roussy), Yang Song(Merck Biopharma Co., Ltd. (Japan)), B. Bui-Nguyen(Institut Bergonié), Joseph Eid(Merck Biopharma Co., Ltd. (Japan)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 243
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k